Philosophy & Strategy

Top Message

Left: Hirokazu Ogino,  President and CEO Right: Takashi Tamura,  Representative Director, Exective Operating Officer Left: Hirokazu Ogino, Representative Director, President and CEO
Right: Takashi Tamura, Representative Director, Exective Operating Officer

First, we would like to sincerely thank our shareholders for your continued support.

We hereby report the results for FY2020 ended March 31, 2021.

In FY2020, the business environment had changed significantly due to the COVID-19 pandemic. In order to fulfill our social responsibility as a medical device manufacturer, the Company focused on ramping up production and maintaining supply of products and services, while implementing thorough measures to prevent infection.
In Japan, sales increased because the Government’s supplementary budget has supported demand in healthcare systems for accepting COVID-19 patients towards the end of FY2020, while medical institutions reduced the number of testing and surgical procedures, and postponed or froze the purchase budget.
Internationally, sales in all regions achieved double-digit growth because demand for patient monitors, ventilators, and defibrillators increased due to the spread of COVID-19.

As a result, the Company posted record highs both in sales and profits in FY2020. As the business performance in FY2020 was favorable, the Company decided to pay the special dividend of 20 yen per share in addition to the ordinary year-end dividend of 18 yen per share. The full-year dividend for FY2020 was 55 yen per share, including the interim dividend of 17 yen per share. The Company also acquired its own shares up to 1.5 billion yen.

In FY2021, the Company started its three-year business plan, BEACON 2030 Phase I. We will strengthen our business foundation to achieve a highly profitable structure that can regularly generate an operating income margin of 10% or more. We will also work to ensure strict compliance and strengthen group governance to become a more trusted company than ever before.

We deeply appreciate your continued support.